Literature DB >> 11106744

ATP-driven chromatin remodeling activity and histone acetyltransferases act sequentially during transactivation by RAR/RXR In vitro.

F J Dilworth1, C Fromental-Ramain, K Yamamoto, P Chambon.   

Abstract

Using a "crude" chromatin-based transcription system that mimics transactivation by RAR/RXR heterodimers in vivo, we could not demonstrate that chromatin remodeling was required to relieve nucleosomal repression. Using "purified" chromatin templates, we show here that, irrespective of the presence of histone H1, both ATP-driven chromatin remodeling activities and histone acetyltransferase (HAT) activities of coactivators recruited by liganded receptors are required to achieve transactivation. DNA footprinting, ChIP analysis, and order of addition experiments indicate that coactivator HAT activities and two ATP-driven remodeling activities are sequentially involved at distinct steps preceding initiation of transcription. Thus, both ATP-driven chromatin remodeling and HAT activities act in a temporally ordered and interdependent manner to alleviate the repressive effects of nucleosomal histones on transcription by RARalpha/RXRalpha heterodimers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106744     DOI: 10.1016/s1097-2765(00)00103-9

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  58 in total

1.  Chromatin disruption and histone acetylation in regulation of the human immunodeficiency virus type 1 long terminal repeat by thyroid hormone receptor.

Authors:  Shao-Chung Victor Hsia; Yun-Bo Shi
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

2.  A role for cofactor-cofactor and cofactor-histone interactions in targeting p300, SWI/SNF and Mediator for transcription.

Authors:  Zhi-Qing Huang; Jiwen Li; Laurent M Sachs; Philip A Cole; Jiemin Wong
Journal:  EMBO J       Date:  2003-05-01       Impact factor: 11.598

3.  A methylation-mediator complex in hormone signaling.

Authors:  Wei Xu; Helen Cho; Shilpa Kadam; Ester M Banayo; Scott Anderson; John R Yates; Beverly M Emerson; Ronald M Evans
Journal:  Genes Dev       Date:  2004-01-16       Impact factor: 11.361

4.  Targeting of SWI/SNF chromatin remodelling complexes to estrogen-responsive genes.

Authors:  Borja Belandia; Rob L Orford; Helen C Hurst; Malcolm G Parker
Journal:  EMBO J       Date:  2002-08-01       Impact factor: 11.598

5.  In vitro transcription system delineates the distinct roles of the coactivators pCAF and p300 during MyoD/E47-dependent transactivation.

Authors:  F Jeffrey Dilworth; Karen J Seaver; Anna L Fishburn; Steve L Htet; Stephen J Tapscott
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

6.  Targeting of Swi/Snf to the yeast GAL1 UAS G requires the Mediator, TAF IIs, and RNA polymerase II.

Authors:  Karine Lemieux; Luc Gaudreau
Journal:  EMBO J       Date:  2004-09-23       Impact factor: 11.598

Review 7.  General molecular biology and architecture of nuclear receptors.

Authors:  Michal Pawlak; Philippe Lefebvre; Bart Staels
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

8.  Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation.

Authors:  Qihuang Jin; Li-Rong Yu; Lifeng Wang; Zhijing Zhang; Lawryn H Kasper; Ji-Eun Lee; Chaochen Wang; Paul K Brindle; Sharon Y R Dent; Kai Ge
Journal:  EMBO J       Date:  2010-12-03       Impact factor: 11.598

9.  Epigenetic mechanism of rRNA gene silencing: temporal order of NoRC-mediated histone modification, chromatin remodeling, and DNA methylation.

Authors:  Raffaella Santoro; Ingrid Grummt
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

10.  Transcription factor interactions and chromatin modifications associated with p53-mediated, developmental repression of the alpha-fetoprotein gene.

Authors:  Thi T Nguyen; Kyucheol Cho; Sabrina A Stratton; Michelle Craig Barton
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.